Designation of Pegaspargase (Oncaspar) as an orphan drug - Baxalta Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and other uses of therapeutic goods in Australia, with the aim of ensuring their quality, safety, and efficacy. The Act was introduced to address the need for a comprehensive regulatory framework governing the therapeutic goods market, thereby protecting public health. This legislation is overseen by the Australian Parliament, with specific implementation and enforcement duties delegated to the Therapeutic Goods Administration (TGA). The policy objective of the Act is to safeguard the health and safety of consumers by ensuring that therapeutic goods meet rigorous standards of quality, safety, and efficacy. In this context, the designation of Pegaspargase (ONCASPAR) as an orphan drug on 6 April 2016 exemplifies the Act's role in facilitating access to critical medications for rare diseases, in this case, Acute Lymphoblastic Leukaemia, by providing incentives for the development and availability of such treatments.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of therapeutic goods, including medicines, within Australia. This Act designates Pegaspargase (ONCASPAR) as an orphan drug specifically for the treatment of patients with Acute Lymphoblastic Leukaemia, under the authority of the Delegate of the Secretary. The scope of this legislation pertains to the approval and regulation of therapeutic goods, ensuring they meet necessary safety, quality, and efficacy standards. Geographically, the Act operates within the Commonwealth of Australia, governing the entire national territory. The designation of Pegaspargase (ONCASPAR) as an orphan drug is an extension of the legislative framework provided under the Therapeutic Goods Regulations 1990, which allows for the classification and regulation of orphan drugs intended for rare diseases. This ensures that such therapeutic goods receive the necessary support and incentives for research and development while maintaining regulatory oversight to protect public health.

Key Provisions

The Therapeutic Goods Act 1989, as amended, includes provisions for the designation of orphan drugs to address rare medical conditions. Section 41-3 of the Act outlines the criteria for designating a drug as an orphan drug, which include the condition it treats being rare and there being no satisfactory methods of diagnosis, prevention, or treatment. In this specific instance, Section 16J of the Therapeutic Goods Regulations 1990 allows for the designation of orphan drugs, with Pegaspargase (ONCASPAR) being designated for the treatment of Acute Lymphoblastic Leukaemia (ALL). This designation acknowledges the rarity of the condition and the need for specialised treatment options. The designation of Pegaspargase (ONCASPAR) as an orphan drug imposes several obligations on the parties involved. Firstly, the sponsor, Baxalta Australia Pty Ltd, must ensure that the drug is manufactured and supplied in accordance with the conditions set out in the regulations. This includes adhering to good manufacturing practices, maintaining proper records, and ensuring the quality and safety of the product. Additionally, the sponsor must provide ongoing data to the Therapeutic Goods Administration (TGA) regarding the drug's safety and efficacy, as required by the regulations. The TGA, in turn, is required to review the provided data and maintain a register of designated orphan drugs, which is made publicly available. The Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 outline various offences and penalties for non-compliance with the provisions governing therapeutic goods. Section 42DA of the Act provides that it is an offence to supply therapeutic goods that do not comply with the standards set out in the regulations. The maximum penalty for this offence is 120 penalty units, which equates to approximately AUD 19,000 as of 2023. Furthermore, Section 42DB of the Act provides that it is an offence to make a false or misleading representation in relation to therapeutic goods, with a maximum penalty of 500 penalty units, or AUD 82,500 as of 2023. These penalties are intended to ensure that therapeutic goods are safe, of high quality, and accurately represented to consumers and healthcare professionals.